U.S. Markets closed

Lexicon Pharmaceuticals, Inc. (LXRX)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
16.70-0.14 (-0.83%)
At close: 4:00PM EDT
People also watch
FOLDARRYDVAXHALOPGNX

Lexicon Pharmaceuticals, Inc.

8800 Technology Forest Place
The Woodlands, TX 77381
United States
281-863-3000
http://www.lexpharma.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees168

Key Executives

NameTitlePayExercisedAge
Mr. Lonnel CoatsChief Exec. Officer, Pres and Director1.05MN/A52
Mr. Jeffrey L. Wade J.D.Chief Financial Officer and Exec. VP of Corp. & Admin. Affairs610.38kN/A52
Dr. Alan J. Main Ph.D.Exec. VP of Commercial Supply Operations518.41kN/A63
Dr. Pablo Lapuerta M.D.Chief Medical Officer and Exec. VP541.51kN/A54
Dr. Praveen Tyle Ph.D.Exec. VP of R&D487.38kN/A57
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products for the treatment of human diseases. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with SSA therapy in adults. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that is in Phase 3 clinical trials for use in the treatment of type 1 and type 2 diabetes; LX2761, which is in Phase 1 development for use in the treatment of diabetes; and LX9211 for use as a treatment for neuropathic pain. The company has license and collaboration agreements with Sanofi; Ipsen Pharma SAS; Bristol-Myers Squibb Company; and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was founded in 1995 and is headquartered in The Woodlands, Texas.

Corporate Governance

Lexicon Pharmaceuticals, Inc.’s ISS Governance QualityScore as of July 1, 2017 is 9. The pillar scores are Audit: 2; Board: 10; Shareholder Rights: 7; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.